Syndax Pharmaceuticals
Yahoo Finance • 8 days ago
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
Kynam Capital Management disclosed in a February 17, 2026, SEC filing that it sold 1,720,949 shares of Cogent Biosciences(NASDAQ:COGT), an estimated $48.38 million trade based on quarterly average pricing. What happened According to a SE... Full story
Yahoo Finance • 8 days ago
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
Kynam Capital Management trimmed its stake in Viridian Therapeutics(NASDAQ:VRDN), selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026,... Full story
Yahoo Finance • 8 days ago
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
Kynam Capital Management reduced its position in CG Oncology(NASDAQ:CGON), selling 1,059,375 shares in the fourth quarter for an estimated $43.84 million based on quarterly average pricing, according to a February 17, 2026, SEC filing. Wh... Full story
Yahoo Finance • 8 days ago
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals(NASDAQ:SNDX), an estimated $8.18 million trade based on quarterly average pric... Full story
Yahoo Finance • 4 months ago
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts – – Retrospective review sh... Full story
Yahoo Finance • 4 months ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the Company granted induceme... Full story
Yahoo Finance • 4 months ago
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will... Full story
Yahoo Finance • 4 months ago
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks with huge upside potential. On November 24, Barclays raised the firm’s price target on Syndax to $35 from $22, while maintaining an Overweight rating on the sha... Full story
Yahoo Finance • 5 months ago
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia... Full story
Yahoo Finance • 5 months ago
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event... Full story
Yahoo Finance • 5 months ago
Syndax Pharmaceuticals Q3 2025 Earnings Preview
* Syndax Pharmaceuticals (SNDX [https://seekingalpha.com/symbol/SNDX]) is scheduled to announce Q3 earnings results on Monday, November 3rd, after market close. The consensus EPS Estimate is -$0.71 [https://seekingalpha.com/symbol/SNDX/e... Full story
Yahoo Finance • 5 months ago
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2025 financial r... Full story
Yahoo Finance • 5 months ago
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
– First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation – – Second approved indication for Revuforj in less than one year further solidifies Sy... Full story
Yahoo Finance • 5 months ago
Syndax gains additional indication for Revuforj in acute myeloid leukemia
[Fda Approved Stamp] atakan * The US FDA has approved Syndax Pharmaceuticals' (NASDAQ:SNDX [https://seekingalpha.com/symbol/SNDX]) Revuforj (revumenib) for relapsed or refractory acute myeloid leukemia in patients with a certain genetic... Full story
Yahoo Finance • 6 months ago
Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best stocks to buy under $20. On September 19, Syndax Pharmaceuticals announced a major milestone: the National Comprehensive Cancer Network/NCCN updated its Clinical Practice Guideli... Full story
Yahoo Finance • 6 months ago
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN... Full story
Yahoo Finance • 7 months ago
Syndax Announces Participation in September Investor Conferences
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as w... Full story
Yahoo Finance • 8 months ago
Citi ups Syndax target, opens ‘upside catalyst watch’
Citi analyst Yigal Nochomovitz raised the firm’s price target on Syndax (SNDX) to $51 from $46 and keeps a Buy rating on the shares. The firm also added a positive “upside catalyst watch” on Syndax ahead of the PDUFA deadline in relapsed o... Full story
Yahoo Finance • 8 months ago
Stocks making the biggest moves midday: Pfizer, Palantir, Coinbase, Staar Surgical and more
Check out some of the companies making the biggest moves midday: Staar Surgical — The implantable eye lens maker ripped 45% higher after agreeing to be bought by Alcon for $28 per share in cash, valuing Staar at about $1.5 billion. The dea... Full story
Yahoo Finance • 8 months ago
Stocks making the biggest premarket moves: Pfizer, Eaton, Palantir, Yum and more
Check out the companies making the biggest moves in premarket trading: Palantir Technologies — The defense technology stock jumped 6.8% after quarterly revenue exceeded $1 billion for the first time and it raised full-year guidance. Palant... Full story
